<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320647">
  <stage>Registered</stage>
  <submitdate>24/09/2009</submitdate>
  <approvaldate>25/09/2009</approvaldate>
  <actrnumber>ACTRN12609000835246</actrnumber>
  <trial_identification>
    <studytitle>Effect of spironolactone versus placebo in patients with a hypertensive response to exercise</studytitle>
    <scientifictitle>The effect of spironolactone versus placebo on fibrosis in patients with a hypertensive response to exercise</scientifictitle>
    <utrn />
    <trialacronym>HRE trial</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Pre-hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1) Spironolactone oral, 25 mg/d, 3 months
2) Exercise - 30 minute sessions of aerobic and resistance training, 5 days per week for 3 months, iincluding 2 supervised small group sessions with an exercise physiologist. 
3) Participants receive these interventions sequentially (ie there are 2 separate treatment arms) 
4) The washout interval will be at least 3 months</interventions>
    <comparator>Placebo oral, 5 mg sugar pill once daily, 3 months</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction of fibrosis, as assessed by backscatter and strain markers</outcome>
      <timepoint>Baseline vs 3 months following randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in diastolic function using tissue Doppler echocardiography, measured as tissue diastolic velocity (e')</outcome>
      <timepoint>Baseline and 3 months following randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Hypertensive response to exercise (HRE); maximum SBP/DBP (systolic/diastolic blood pressure) response to exercise &gt;210/105 mmHg in men and &gt;190/105 mmHg for women</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) hypertension at rest (&gt;140/90 mmHg or on treatment for hypertension), 2) known coronary artery disease (angina, previous infarction, previous positive diagnostic test), 3) diabetes mellitus</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Computer entry of recruitment data produces a coded prescription which is filled by a pharmacist independent of the trial. Identity of patients on each treatment is kept at pharmacy and released when the databse is locked</concealment>
    <sequence>Computer-generated</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>12/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Queensland</primarysponsorname>
    <primarysponsoraddress>Research Training Division
The University of Queensland
Brisbane QLD 4072</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation</fundingname>
      <fundingaddress>Level 12, 500 Collins Street 
Melbourne
VIC 3003</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aims of this study are to show that patients with hypertension and abnormal left ventricular (LV) filling (but without coronary artery disease) may have their echocardiographic and biochemical markers of myocardial fibrosis and diastolic function improved by treatment with spironolactone, an aldosterone antagonist with anti-fibrotic properties.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital Research Ethics Committee</ethicname>
      <ethicaddress>Princess Alexandra Hospital 
Ipswich Road
Brisbane
Qld 4102</ethicaddress>
      <ethicapprovaldate>21/08/2006</ethicapprovaldate>
      <hrec>2001/113</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr T Marwick</name>
      <address>University of Queensland Dept of Medicine
Princess Alexandra Hospital
Brisbane, Qld 4102</address>
      <phone>+61-7-3240-5345</phone>
      <fax>+61-7-3240-5399</fax>
      <email>t.marwick@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr T Marwick</name>
      <address>University of Queensland Dept of Medicine
Princess Alexandra Hospital
Brisbane, Qld 4102</address>
      <phone>+61-7-3240-5345</phone>
      <fax>+61-7-3240-5399</fax>
      <email>t.marwick@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr T Marwick</name>
      <address>University of Queensland Dept of Medicine
Princess Alexandra Hospital
Brisbane, Qld 4102</address>
      <phone>+61-7-3240-5345</phone>
      <fax>+61-7-3240-5399</fax>
      <email>t.marwick@uq.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>